Madam Chair, I am doing that, because in fact the fundamental issue at stake here is the question of conflict of interest and the question of a vice-president of Pfizer being appointed to the CIHR. When in fact we have someone coming to this committee to defend that appointment who also gets a considerable amount of money from Pfizer, I think it's rather important for the committee to know this and rather important for me to pursue a line of questioning that at least establishes the credibility of the witnesses on this particular issue.
On December 7th, 2009. See this statement in context.